$76.83
-0.21[-0.27%]
At close: May 17
$76.83
0[0.00%]
PreMarket: 6:35AM EDT
AstraZeneca
(NASDAQ:AZN)Latest News for AstraZeneca Stock (NASDAQ:AZN)
AstraZeneca Stock (NASDAQ: AZN)
Categories: All
Thursday, May 16, 2024
- AstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data ShowsVandana Singh - 19 hours ago
- Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma GameUpwallstreet - 22 hours ago
- AstraZeneca's High-level Results From SUPERNOVA Phase 3 Covid-19 Pre-exposure Prophylaxis Trial Showed Sipavibart (AZD3152) Reduced The Incidence Of Symptomatic Covid‑19 Vs. Control (Tixagevimab/Cilgavimab Or Placebo) In Immunocompromised PatientsBenzinga Newsdesk - 1 day ago
Monday, May 13, 2024
Thursday, May 09, 2024
Wednesday, May 08, 2024
Tuesday, May 07, 2024
Monday, May 06, 2024
Thursday, May 02, 2024
- 10 Health Care Stocks Whale Activity In Today's SessionBenzinga Insights - May 2, 2024, 1:35PM
- AstraZeneca's High-Level Results From Interim Analysis Of ECHO Phase 3 Trial Of Calquence Combo Regime, Showed Statistically Significant, Clinically Meaningful Improvement In Progression-Free Survival Versus SoC In Untreated Mantle Cell Lymphoma PatientsBenzinga Newsdesk - May 2, 2024, 5:10AM
- Beyfortus Real-World Evidence Published In The Lancet Shows 82% Reduction In Infant RSV HospitalizationsBenzinga Newsdesk - May 2, 2024, 3:12AM
Wednesday, May 01, 2024
- Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZenecaVandana Singh - May 1, 2024, 4:11PM
- Astrazeneca Disclosed Latest Research Across Key Respiratory And Immune-mediated Diseases At ATS 2024 Showcasing Strength Of Its Broad Pipeline And PortfolioBenzinga Newsdesk - May 1, 2024, 7:27AM
Monday, April 29, 2024
- AstraZeneca Admits Its COVID-19 Vaccine May Cause Blood Clotting Side Effect In Very Rare Case, But Causal Mechanism UnknownVandana Singh - Apr 29, 2024, 2:38PM
- Double Good News For AstraZeneca's Breast Cancer DrugsVandana Singh - Apr 29, 2024, 9:25AM
- On Sunday Telegraph Reported That AstraZeneca Admits For First Time In Court Documents Its Covid Vaccine Can Cause Rare Side Effect, The Company Is Being Sued In Class Action Over Claims Its Vaccine Caused Death And Serious Injury In Dozens Of CasesBenzinga Newsdesk - Apr 29, 2024, 7:44AM
- Daiichi Sankyo And AstraZeneca's ENHERTU Shows Statistically Significant And Clinically Meaningful Improvement In HR+, HER2 Low Breast Cancer: DESTINY-Breast06 Trial ResultsBenzinga Newsdesk - Apr 29, 2024, 3:14AM
- Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This WeekShanthi Rexaline - Apr 29, 2024, 1:51AM
Friday, April 26, 2024
Thursday, April 25, 2024
- AstraZeneca, Through A Subsidiary, Will Acquire All Of Fusion's Outstanding Shares For A Price Of $21.00 Per Share In Cash At Closing Plus A Non-Transferable CVR Representing The Contingent Right To Receive $3.00/Share In Cash Payable Upon The Achievement Of A Specified Regulatory Milestone, Pursuant And Subject To The Terms And Conditions Of A Contingent Value Rights AgreementBenzinga Newsdesk - Apr 25, 2024, 5:12PM
- Is "Bad News" Still "Good News" for the Market?Zacks - Apr 25, 2024, 2:40PM
- Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionAvi Kapoor - Apr 25, 2024, 1:57PM
- Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?Piero Cingari - Apr 25, 2024, 1:30PM
- Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On ThursdayAvi Kapoor - Apr 25, 2024, 10:15AM
- AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual GuidanceVandana Singh - Apr 25, 2024, 9:03AM
- US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says AnalystShanthi Rexaline - Apr 25, 2024, 6:17AM
- AstraZeneca shares are trading higher following a Q1 revenue beat.Benzinga Newsdesk - Apr 25, 2024, 6:05AM
- AstraZeneca Reiterates Its 2024 Guidance: Expects Total Revenue And Core EPS To Increase By A Low Double-Digit To Low Teens Percentage At CERBenzinga Newsdesk - Apr 25, 2024, 2:09AM
- AstraZeneca Q1 2024 Adj EPADS $1.03 Misses $1.22 Estimate, Sales $12.679B Beat $11.833B EstimateBenzinga Newsdesk - Apr 25, 2024, 2:07AM
Wednesday, April 24, 2024
Monday, April 22, 2024
Sunday, April 21, 2024
Friday, April 19, 2024
Wednesday, April 17, 2024
Tuesday, April 16, 2024
- Deutsche Bank Upgrades AstraZeneca to HoldBenzinga Newsdesk - Apr 16, 2024, 2:17PM
- AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data ShowsVandana Singh - Apr 16, 2024, 8:53AM
- AstraZeneca's Imfinzi Plus Chemotherapy Doubled Overall Survival Rate At Three Years For Patients With Advanced Biliary Tract Cancer In TOPAZ-1 Phase 3 TrialBenzinga Newsdesk - Apr 16, 2024, 5:22AM
Friday, April 12, 2024
Thursday, April 11, 2024
- AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO's Pay Package BoostVandana Singh - Apr 11, 2024, 9:04AM
- AstraZeneca shares are trading higher following FDA approval of FASENRA. Additionally, the company raised its 2024 dividend by 7%.Benzinga Newsdesk - Apr 11, 2024, 8:50AM
- FDA Approves AstraZeneca's Fasenra (Benralizumab) For Add-on Maintenance Treatment For Patients With Severe Asthma Aged 6 To 11 With An Eosinophilic PhenotypeBenzinga Newsdesk - Apr 11, 2024, 7:02AM
- Earlier Astrazeneca Announced Increase In 2024 Dividend By 7% To $3.10/ShareCharles Gross - Apr 11, 2024, 5:17AM